Home›Trial›NCT06449222
🔬NCT06449222Phase 2ACTIVE NOT RECRUITING

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Study Summary

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

Conditions
Locally Advanced Breast CancerTriple Negative Breast CancerMetastatic Triple Negative Breast Cancers
Interventions / Drugs
BNT327 Dose Level 1 (DL1)BNT327 Dose Level 1 (DL2)Nab-placlitaxelCarboplatinGemcitabinePaclitaxelEribulinBNT327 Optimized DoseBNT327 Equivalent Q3W Dose
View on ClinicalTrials.gov ↗
Sponsor
BNTX
BioNTech SE
mRNA Therapeutics
F20/100
Study Details
Enrollment83 participants
Primary Completion—
Lead SponsorBioNTech SE
Data Retrieved2026-04-11 02:55:25.057698+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.